Pharmalink (private company)

Pharmalink is a specialty pharma company developing high-value, global products for patients with significant unmet medical needs.
Pharmalink is focused on the development and commercialisation of its lead product candidate Nefecon, which has successfully completed a Phase 2b clinical trial as a potential new treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure.